Billboards with 800-Get-Thin on them were all over California until the Food and Drug Administration said they failed to disclose the risks of weight loss surgery. Then came state and federal lawsuits alleging that the 800-Get-Thin centers were defrauding insurers. Now, 800-Get-Thin surgery centers are suing the UnitedHealth Group Inc. (NYSE:UNH) to get the $100 million they claim they are owed. UnitedHealth Group Inc. (NYSE:UNH) stock performance was -1.66% in last session and finished the day at $78.19. Traded volume was 8.10million shares in the last session and the average volume of the stock remained 5.00million shares. The beta of the stock remained 0.62. UnitedHealth Group Inc. (NYSE:UNH) insider ownership is 0.70%.
Jerusalem-based Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) launched on April 15 a generic equivalent to Lunesta, 1, 2 and 3 mg, in the United States. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) rose 0.60 percent to $49.91 Wednesday on volume of 6.62million shares. The intra-day range of the stock was $49.90 to $50.52. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has a market capitalization of $47.40billion.
Allergan, Inc. (NYSE:AGN) the leader in the medical aesthetics category, announced that the company had received approval from the U.S. Food and Drug Administration to market JUVÉDERM VOLUMA™ XC, the first and only filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. Allergan, Inc. (NYSE:AGN)’s stock on Apr 16, 2014 reported a increase of 2.86% to the closing price of $131.46. Its fifty two weeks range is $81.33 -$132.04. The total market capitalization recorded $39.32billion. The overall volume in the last trading session was 5.87million shares. In its share capital, AGN has 299.11million outstanding shares.
In March Reckitt acquired the global rights to the K-Y sexual lubricant brand from Johnson & Johnson Inc. Last May, it paid Bristol-Myers Squibb Co. (NYSE:BMY) $482 million upfront for the exclusive rights to sell, distribute and market seven over-the-counter medicines, including cold, flu and indigestion treatments, for a three-year period. The products are mainly sold in Latin America. On Wednesday, shares of Bristol-Myers Squibb Co (NYSE:BMY) advanced 1.95% to close the day at $49.11. Company return on investment (ROI) is 10.70% and its monthly performance is recorded -9.64%. Bristol-Myers Squibb Co (NYSE:BMY) quarterly revenue growth is -9.26%.
Leave a Reply